Charting Survivin specific T cells in cancer patients with Head and Neck Squamous Cell Carcinoma

Charting Survivin specific T cells in cancer patients with Head and Neck Squamous Cell Carcinoma - Charting Survivin specific T cells in HNSCC patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33346

Enrollment

Registered

2009-10-22

Start date

2010-04-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck cancer HNSCC

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: The patients in this study must have a histological confirmation of Head and Neck carcinoma stage 3 or higher. Patients must be over 18 years of age. There is no maximum age. Patients must be capable of giving informed consent. Patients must have a life expectancy of at least 3 months. Patients must be HLA-A2 positive.

Exclusion criteria

Exclusion criteria: Patients are excluded when pregnant. Patients are excluded when anemic.

Design outcomes

Primary

Measure	Time frame
Primary; Charting the presence of tumour specific T cells will be performed employing tetramer staining. In house made HLA-A1 and HLA-A2 tetramers will be used to detect T cells directed against known antigenic peptide sequences derived from the tumour antigen survivin. This will document the presence of T cells with such specificities as a percentage of total CD8 positive T cells. It is expected that in about half of the patients survivin specific T cells will be detectable.	—

Measure

Time frame

Primary; Charting the presence of tumour specific T cells will be performed employing tetramer staining. In house made HLA-A1 and HLA-A2 tetramers will be used to detect T cells directed against known antigenic peptide sequences derived from the tumour antigen survivin. This will document the presence of T cells with such specificities as a percentage of total CD8 positive T cells. It is expected that in about half of the patients survivin specific T cells will be detectable.

—

Secondary

Measure	Time frame
Secondary; Since tetramers are available containing antigenic peptides derived from tumour antigens other than survivin, it is possible to chart the immune reactivity against these antigens simultaneously. We will do so employing tetramers with a fluorescent marker different form the one used for survivin. Tertiary; Tetramer positive T cells will be isolated from these samples when possible.	—

Countries

Netherlands

Outcome results